Blue Lake Bio

Blue Lake Bio is a clinical-stage biotechnology company developing next-generation intranasal vaccines using its proprietary PIVOT (Parainfluenza Virus 5 Vector) platform. This technology utilizes a modified parainfluenza virus 5 (PIV5) to deliver vaccine antigens, inducing robust mucosal, cellular, and humoral immunity without the need for needles. The company's lead program, BLB-201, is an intranasal vaccine for Respiratory Syncytial Virus (RSV) currently being evaluated in clinical trials for pediatric and elderly populations. Additionally, Blue Lake Bio is advancing vaccine candidates for COVID-19, human metapneumovirus, and norovirus, aiming to provide superior protection against respiratory and infectious diseases. The company is a spin-off of CyanVac and leverages extensive expertise in viral vector technology.